Hylenex
Sponsors
Halozyme Therapeutics, Vanderbilt University Medical Center, Tissa Hata, MD, Steve Yoelin M.D. Medical Associates, Inc., Pablo Tebas
Conditions
Cardiac OutputDehydrationDermal FillerHealthyHealthy VolunteersPainPediatricsPsoriasis
Phase 1
A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase
CompletedNCT00435604
Start: 2007-02-28End: 2007-05-31Target: 15Updated: 2011-10-17
The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers
CompletedNCT02654522
Start: 2016-01-31End: 2016-02-29Updated: 2017-05-16
dMAbs for Prevention of COVID-19
CompletedNCT05293249
Start: 2022-05-19End: 2025-11-21Updated: 2026-01-22
Phase 2
Phase 3
Phase 4
A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects
CompletedNCT00311519
Start: 2005-11-30End: 2006-01-31Target: 50Updated: 2006-04-06
Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics
CompletedNCT01139294
Start: 2010-02-28End: 2011-11-30Updated: 2018-02-01